Phosphorylase Inhibitor

CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes.

TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC₅₀ of 12.5 μM and human small intestinal UPase with an IC₅₀ of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis.

Ingliforib (CP 368296) is a glycogen phosphorylase inhibitor, with IC₅₀s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.

Bayogenin is a triterpenoid saponin and one of the main components of Medicago sativa saponins. Bayogenin is an inhibitor of glycogen phosphorylase.

hUP1-IN-1 potassium (compound 6a) is a hUP1 inhibitor with K_ii and K_is Urd of 375 and 635 nM. hUP1-IN-1 potassium showes inhibitory activities over hUP1 catalyzed reaction with 70% at 1 μM. hUP1-IN-1 potassium can be used for the research of cancer.

AVE5688 is an inhibitor of glycogen phosphorylase (GP), with IC₅₀s of 430 nM and 915 nM and K_ds of 170 nM and 530 nM for rabbit muscle glycogen phosphorylase (rmGPb and rmGPa, respectively); AVE5688 can be used for the research of type 2 diabetes.

Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC₅₀s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes.

Glycogen phosphorylase-IN-2 (compound 9C) is an inhibitor of glycogen phosphorylase with a K_i value of 1.9 nM and an IC₅₀ value of 4 nM.

CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC₅₀=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes.

Bayogenin (Standard) is the analytical standard of Bayogenin (HY-N1932). This product is intended for research and analytical applications. Bayogenin is a triterpenoid saponin and one of the main components of Medicago sativa saponins. Bayogenin is an inhibitor of glycogen phosphorylase.

BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC₅₀ values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes.

GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC₅₀s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively. GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia.

hUP1-IN-1 is a hUP1 inhibitor with K_ii and K_is Urd of 375 and 635 nM. hUP1-IN-1 showes inhibitory activities over hUP1 catalyzed reaction with 70% at 1 μM. hUP1-IN-1 can be used for the research of cancer.

CP-316819 (GPi 819) Standard is the analytical standard of CP-316819 (HY-108615). This product is intended for research and analytical applications. CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes.

Deoxyadenosine diphosphate sodium is a nucleoside diphosphate, in which the nucleoside is deoxyadenosine. Deoxyadenosine diphosphate sodium participates in DNA synthesis and repair. Deoxyadenosine diphosphate sodium acts as the inhibitor of polynucleotide phosphorylase, interfers with the polymerization of ADP and CDP.

Domiphen bromide (Standard) is the analytical standard of Domiphen bromide (HY-B1467). This product is intended for research and analytical applications. Domiphen bromide is a cationic active quaternary ammonium salt and also an inhibitor of HERG channels (IC₅₀: 9 nM), aminopeptidase-like enzymes, Escherichia coli alkaline phosphatase, and α-chymotrypsin. Domiphen bromide has multiple activities such as antibacterial, antimalarial, and disinfectant properties, and it is also a synergist of Colistin (HY-113678). Domiphen bromide can be used as a chemical preservative and a cationic surfactant, and it can also be used in the research of bacterial infectious diseases such as pharyngitis, thrush, and oral ulcers.

RMGPa-IN-1 (Compound 10C) is a rabbit muscle glycogen phosphorylase a (RMGPa) inhibitor with an IC₅₀ value of 82.5 μM. RMGPa-IN-1 is promising for research of diabetes.

hUP1-IN-2 is a Urd-competitive and Pᵢ-noncompetitive hUP1 inhibitor with K_i values of 68 nM and 127 nM, respectively. hUP1-IN-2 reduces the toxicity of 5-fluorouracil (HY-90006) against colon cancer. hUP1-IN-2 can be used in the research of colon cancer.

8-Aminoguanosine is a purine nucleoside phosphorylase inhibitor. 8-Aminoguanosine blocks purine nucleoside phosphorylation via specific binding.